What's breaking now, across thousands of outlets.
An assessment for the HSE of the weight-loss drug Wegovy has found that it is cost-effective and value for money, and should be made available to certain public patients, despite the high budget impact.
We haven't written up this one. RTE News has the full story — the link below goes straight to it.
Learn about a new blood test that could lead to earlier detection and treatment of breast cancer.
Healthcare students can use the Clasp Marketplace to compare jobs by what each one pays toward their student loans, plus salaries.
The clinic will combine Millie’s midwifery care model with El Camino’s labor and delivery services and broader specialist network.
The protester was hit, kicked, and slapped by police allegedly because he was participating in a video recording documenting police violence towards detainees; his right ear drum was perforated in the…
Genetic testing that helps doctors select the right antidepressant for a patient did not lead to better improvements in depressive symptoms than standard prescriptions based on clinical guidelines…
(MedPage Today) -- Patients with non-erosive reflux disease (NERD) who took once-daily tegoprazan -- a novel, fast-acting, oral potassium-competitive acid blocker (P-CAB) -- had a significant…
